Different doses of pamidronate in patients with painful osteolytic bone metastases

Supportive Care in Cancer

Volumn 6, Issue 2, 1998, Pages 139-143

  Cascinu, Stefano ^a   Graziano, Francesco ^a   Alessandroni, Paolo ^a   Ligi, Marco ^a   Del Ferro, Elena ^a   Rossi, David ^a   Ficarelli, Rita ^a   Catalano, Giuseppina ^a  

^a Azienda Ospedaliera Ospedale   (Italy)

Author keywords

Bone metastases; Pamidronate

Indexed keywords

DICLOFENAC; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE PAIN; DOSE RESPONSE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; OSTEOLYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CARCINOMA; DIPHOSPHONATES; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN, INTRACTABLE; TREATMENT OUTCOME;

EID: 0031911158     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200050148     Document Type: Article

References (19)

1. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493
2. Body JJ, Dumon JC, Piccart M, Ford J (1995) Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. J Bone Miner Res 10:1191-1196
3. Burckhardt P, Thiebaud D, Perey L, von Fliedner V (1989) Treatment of tumor-induced osteolysis by APD. Recent Results Cancer Res 116:54-66
4. Cascinu S, Casadei V, Del Ferro E, Alessandroni P, Catalano G (1996) Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Support Care Cancer 4:31-33
5. Coleman RE, Woll PJ, Miles H, Scrivener W, Rubens RD (1988) Treatment of bone metastases from breast cancer with (3-amino-1hydroxypropylidene)-1,1-biphosphonate (APD). Br J Cancer 58:621-625
6. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, Ford JM (1994) Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Ann Oncol 5 [Suppl 7]:41-44
7. Fitton A, McTavish A (1991) Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drug 41:289-318
8. Fleisch H (1989) Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. In: Brunner KW, Fleisch H, Senn HJ (eds) Biphosphonates and tumor osteolysis. Recent Results Cancer Res 116: 1-28
9. Glantz SA (1992) Primer of biostatistics, 4th edn. McGraw-Hill, New York
10. Glover D, Lipton A, Keller A, Miller AA, Browning S, Fram RJ, George S, Zelenakas K, Macerata RS, Seaman JJ (1994) Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer 74:2949-2955
11. Hortobagy GN, Theriault RL, Poerter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD, Heffernan M, Reitsma DJ (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785-1791
12. Kanis JA, McCloskey EV, Taube T, O'Rourke N (1991) Rationale for the use of bisphosphonates in bone metastases. Bone 12 [Suppl 1]: 1-6
13. Koeberle D, Thurlinman B, Engler H, Bacchus L, Senn HJ, Riesen W (1997) Double blind intravenous pamidronate (APD) 60 mg versus 90 mg in patients with malignant osteolytic bone disease and pain. Proc Am Soc Clin Oncol 16:182
14. Morton AR, Dodwell DJ, Howell A (1989) Disodium pamidronate infusion for bone metastases: clinical trial in patients with breast carcinoma. In: Burkhardt P (ed) Disodium pamidronate in the treatment of malignancy-related disorders. Huber, Toronto, pp 120-133
15. Purohit OP, Antonhy C, Radstone CR, Owen J, Coleman RE (1994) High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 70:554-558
16. Thurlimann B (1994) Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effect? Ann Oncol 5 [Suppl 7]:45-47
17. Thurliman B, Morant R, Jungi WF, Radzwill A (1994) Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 2:61-65
18. Van Holten-Verzantvoort ATM, Zwinderman AH, Aaronson NK, Hermans J, van Hemmerik B, van Dam F SAM, van der Bos B, Bijvoet OLM, Lleton FJ (1991) The effects of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27:544-549
19. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex IVAM, Hermans J, Neijt JP, Papapoulos SE, Sleeboom SE, Vermey P, Zwinderman AH (1993) Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11:491-498